MasaomiNangaku TokyoJapan

• Welcome and ISN Presidential Address
  MarcelloTonelli Speaker cello@ucalgary.caCanada
• Jean Hamburger Award Presentation
• Welcome Speech by JSN President
  MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
• Welcome Speech by APSN President
  XueqingYu Speaker yuxueqing@gdph.org.cnChina
• Dynamics of the Function and Regulation of the Endoplasmic Reticulum
  KazutoshiMori Speaker mori.kazutoshi.8r@kyoto-u.ac.jpJapan
• ISN Film Event Winner Presentation

• Advanced Data Science in CKD Management
  YuichiroYano Speaker y.yano@juntendo.ac.jpJapan
• An Integrated Approach to Cardio-Renal-Metabolic Disorders : Addressing Hypertension and Dyslipidemia
  KOUICHITAMURA Speaker tamukou@yokohama-cu.ac.jpJapan

• Opening Remarks and Session Overview
  AdeeraLevin Speaker alevin@providencehealth.bc.caCanada
• Overcoming the Bottleneck: Endpoint Selection in Phase 2 Kidney Trials
  Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deGermany
• Integrating Patient-Reported Outcomes (PROMs)
  Using Patient-reported Outcomes to Improve Kidney Research and Care
  AllisonJaure Speaker allison.jaure@sydney.edu.auAustralia
• Rethinking Kidney Trials: Innovative Designs for Modern Research Questions
  MegJardine Speaker meg.jardine@sydney.edu.auAustralia
• Designing Better Kidney Trials Using Hierarchical Composite Endpoints
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Panel Discussion & Q&A
• Closing Remarks
  MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan

• Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL trial
  KatherineTuttle Speaker Katherine.Tuttle@providence.orgUnited States
• Multiparametric Imaging and Tissue Transcriptomics to Unravel Mechanisms of Kidney Protection
  MatthiasKretzler Speaker kretzler@umich.eduUnited States
• GLP1s in Combination With Other Therapies and Applications in Clinical Practice
  BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia
• The Future of GLP1s and Other Incretin-based Therapies for Kidney Disease
  MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan

• Is Kidney Dysfunction in Heart Failure More Than Just Low Cardiac Output?
  BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia
• Is Metabolic Dysfunction in Cardiovascular-Kidney-Metabolic Syndrome More Than Just Hyperglycemia and Obesity?
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Kidney at the Center of Cardiovascular-Kidney-Metabolic Syndrome
  MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
• What’s Next in Cardiovascular-Kidney-Metabolic Therapy?
  RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States
• Q&A

• Welcome & Introductions
  MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
• UACR: The hidden marker of heart and kidney risk
  PamelaKushner Speaker pamkushner@hotmail.comUnited States

  RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States
• Live Q&A
  MasaomiNangaku Moderator. mnangaku@m.u-tokyo.ac.jpJapan
• The Impact of RAAS Dysregulation in Cardiorenal Disease
  Sydney Tang Speaker scwtang@hku.hkHong Kong, China
• Live Q&A
  MasaomiNangaku Moderator. mnangaku@m.u-tokyo.ac.jpJapan
• Closing Remarks
  MasaomiNangaku Moderator mnangaku@m.u-tokyo.ac.jpJapan

• The Future of Lupus Nephritis: Achieving Renal Protection Through Proteinuria Control
  SHOICHIMARUYAMA Speaker marus@med.nagoya-u.ac.jpJapan
• A New Era in Lupus Nephritis: Clinical Evidence and Therapeutic Positioning of Triple Therapy
  KeijuHiromura Speaker hiomura@gunma-u.ac.jpJapan